CrownBio
CrownBio’s metabolic disease portfolio is a unique continuum of translational platforms that enable our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development. Our clients engage with these translational platforms, which include rodent and non-human primates, (NHP) to model human liver disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.